Tag: MONOGRAPH

  • Saroglitazar

    Dual peroxisome proliferator-activated receptor alpha/gamma (PPARalpha/gamma) agonist with predominant PPARalpha activity

    A first-in-class dual PPARalpha/gamma agonist developed by Zydus Cadila as the first new chemical entity discovered and approved in India, indicated for diabetic dyslipidemia and non-cirrhotic non-alcoholic steatohepatitis, and under clinical investigation for primary biliary cholangitis and metabolic dysfunction-associated steatotic liver disease in the United States.

    Abstract

    Saroglitazar, the magnesium salt of (2S)-2-ethoxy-3-[4-(2-{2-methyl-5-[4-(methylsulfanyl)phenyl]-1H-pyrrol-1-yl}ethoxy)phenyl]propanoic acid, is a first-in-class dual agonist of peroxisome proliferator-activated receptors alpha and gamma (PPARalpha/gamma) with predominant PPARalpha and moderate PPARgamma activity. Developed by Zydus Cadila (now Zydus Lifesciences) under the development code ZYH1, it was the first new chemical entity discovered entirely in India to receive marketing authorization, granted in 2013 by the Drug Controller General of India for the treatment of diabetic dyslipidemia and hypertriglyceridemia in patients with type 2 diabetes mellitus not controlled by statins alone. In 2020, saroglitazar received a second indication in India for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH), making it the first drug approved anywhere in the world for that condition.

    The dual PPARalpha/gamma mechanism provides a pharmacological profile that bridges the lipid-lowering activity of fibrates (PPARalpha agonists) with the insulin-sensitizing activity of thiazolidinediones (PPARgamma agonists) while avoiding the weight gain, edema, and cardiovascular risk signals that led to the withdrawal of earlier glitazar-class compounds (muraglitazar, tesaglitazar, ragaglitazar). PPARalpha activation increases hepatic fatty acid beta-oxidation, reduces triglyceride synthesis, and elevates high-density lipoprotein cholesterol. PPARgamma activation enhances peripheral insulin sensitivity in adipose and skeletal muscle tissue, reduces hepatic gluconeogenesis, and modulates adipokine secretion. The dual activation also provides anti-inflammatory and antifibrotic effects in the liver through suppression of nuclear factor kappa B signaling, reduction of pro-inflammatory cytokines (tumor necrosis factor alpha, interleukin-6, interleukin-1 beta), and modulation of the leptin-to-adiponectin ratio.

    Pharmacokinetics in healthy human subjects are characterized by rapid oral absorption (median time to peak plasma concentration of 0.6 to 1.0 hours under fasting conditions), extensive plasma protein binding (approximately 96 percent), hepatic metabolism to saroglitazar sulfoxide and other metabolites, and a terminal elimination half-life of approximately 3 to 6 hours depending on sex and formulation. The compound does not accumulate on repeated once-daily dosing, and food does not meaningfully affect overall systemic exposure. The pharmacokinetic profile has been characterized in healthy volunteers, in patients with hepatic impairment (including cholestatic cirrhosis), and in patients with renal impairment.

    The clinical evidence base spans multiple Phase 2 and Phase 3 programs. The PRESS series of trials (PRESS I through PRESS VIII) established efficacy in diabetic dyslipidemia and hypertriglyceridemia, demonstrating non-inferiority to fenofibrate for triglyceride reduction and superiority to pioglitazone for lipid parameter improvement. The EVIDENCES series of trials evaluated saroglitazar in non-alcoholic fatty liver disease (NAFLD) and NASH, with the EVIDENCES II Phase 3 trial in India demonstrating significant histological improvement at 52 weeks. A US-based Phase 2 trial (Gawrieh et al. 2021) in 106 patients with biopsy-proven NASH demonstrated significant improvement in NAFLD activity score, liver enzymes, and lipid parameters at 16 weeks. In primary biliary cholangitis (PBC), the Phase 2 proof-of-concept study demonstrated a 49 to 51 percent reduction in alkaline phosphatase at 16 weeks in ursodeoxycholic acid-resistant or -intolerant patients, and the Phase IIb/III EPICS-III trial met its primary and secondary endpoints; regulatory submission to the United States Food and Drug Administration for this indication is anticipated in the first quarter of 2026. The compound has received orphan drug designation and Fast Track designation from the FDA for PBC.

    The absence of the thiazolidinedione-class adverse events (peripheral edema, weight gain, bone fracture, bladder cancer signal) is attributed to the predominant PPARalpha and moderate PPARgamma pharmacological balance. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Bacoside A

    Dammarane-type triterpenoid saponin mixture with multi-target nootropic, antioxidant, and neuroprotective activity

    A mixture of dammarane-type triterpenoid saponin glycosides isolated from Bacopa monnieri (Linn.) Wettst., constituting the principal bioactive fraction responsible for the cognitive-enhancing, neuroprotective, and antioxidant pharmacology of the Ayurvedic nootropic brahmi, with demonstrated activity across cholinergic modulation, serotonergic and dopaminergic neurotransmission, amyloid-beta aggregation inhibition, and synaptic plasticity.

    Abstract

    Bacoside A is a mixture of four dammarane-type triterpenoid saponin glycosides (bacoside A3, bacopaside II, bacopasaponin C, and bacopaside X) isolated from the aerial parts and roots of Bacopa monnieri (Linn.) Wettst. (family Plantaginaceae, formerly Scrophulariaceae), a creeping perennial herb used in the Ayurvedic medical tradition for over three millennia under the name brahmi as a medhya rasayana (intellect-rejuvenating) agent. The bacoside A fraction, typically comprising 40 to 55 percent of standardized Bacopa monnieri extracts by weight, is the principal pharmacologically active constituent and the basis of standardization for all clinically studied Bacopa preparations including CDRI-08 (KeenMind, Synapsa), BacoMind, and BaCognize. The aglycone cores of the constituent saponins are jujubogenin and pseudojujubogenin, linked to arabinose-glucose trisaccharide chains that modulate solubility, bioavailability, and receptor interaction profiles.

    The pharmacology of bacoside A is multi-target and operates through at least five characterized mechanisms: (1) enhancement of cholinergic neurotransmission through upregulation of choline acetyltransferase activity and inhibition of acetylcholinesterase; (2) modulation of serotonergic neurotransmission through interaction with 5-HT1A and 5-HT2C receptor subtypes, with downstream effects on anxiety, mood, and cognitive flexibility; (3) dopaminergic modulation in prefrontal and hippocampal circuits; (4) potent antioxidant neuroprotection through scavenging of reactive oxygen species, suppression of lipid peroxidation, and upregulation of endogenous antioxidant enzymes including superoxide dismutase, catalase, and glutathione peroxidase; and (5) inhibition of amyloid-beta peptide fibrillation and cytotoxicity through direct interaction with amyloid-beta (1-42), reducing aggregation and membrane disruption in neuronal cell models. Additional mechanisms include enhancement of brain-derived neurotrophic factor (BDNF) expression, promotion of hippocampal dendritic branching and synaptic density in the CA1 and CA3 regions, and modulation of GABAergic neurotransmission.

    The clinical evidence base for Bacopa monnieri standardized to bacoside A content comprises at least nine randomized, double-blind, placebo-controlled trials in healthy adults, elderly populations, and children, conducted principally at Swinburne University of Technology (Stough laboratory), the University of Wollongong (Roodenrys laboratory), and multiple Indian academic medical centers. Effect onset requires sustained administration; acute single-dose cognitive enhancement has not been reliably demonstrated. A 2012 systematic review by Pase et al. confirmed the cognitive-enhancing effects across six qualifying trials and identified memory consolidation as the most reproducible endpoint.

    Pharmacokinetic characterization of isolated bacoside A in humans remains incomplete. In silico ADMET analyses of the constituent saponins and their aglycone derivatives indicate favorable predicted oral absorption for the aglycones (jujubogenin, pseudojujubogenin), with central nervous system drug-like properties including adequate predicted blood-brain barrier penetration. The intact glycosides are poorly water-soluble and are believed to undergo gastrointestinal hydrolysis to active aglycone metabolites, a transformation consistent with the delayed onset of clinical effect observed in human trials. Hepatic metabolism involves cytochrome P450 enzymes; Bacopa monnieri standardized extract has been demonstrated to inhibit CYP3A4, CYP2C9, CYP2C19, and CYP1A2 in vitro at estimated gut concentrations, with potential for clinically significant herb-drug interactions.

    The principal adverse events are mild gastrointestinal disturbances (nausea, abdominal cramps, increased stool frequency) that typically attenuate with continued use. No hepatotoxicity has been reported despite widespread use. A thyroid-stimulating effect (elevation of serum T4) has been characterized in animal studies and warrants caution in individuals with thyroid disorders. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • GlyNAC

    Glutathione precursor amino acid combination providing glycine and N-acetylcysteine as rate-limiting substrates for intracellular glutathione biosynthesis

    A defined combination of glycine and N-acetylcysteine developed at Baylor College of Medicine as a glutathione-replenishing intervention targeting age-associated oxidative stress, mitochondrial dysfunction, and multiple hallmarks of biological aging.

    Abstract

    GlyNAC is a defined equimolar combination of glycine and N-acetylcysteine (NAC) that supplies the two amino acid precursors whose availability limits the intracellular biosynthesis of glutathione (gamma-glutamylcysteinylglycine, GSH), the most abundant endogenous non-protein thiol antioxidant in mammalian cells. The combination was developed and systematically investigated by Rajagopal V. Sekhar and colleagues at Baylor College of Medicine beginning approximately 2018, on the basis of prior observations that aging, HIV infection, and type 2 diabetes are associated with deficient intracellular glutathione concentrations traceable to diminished availability of both glycine and cysteine rather than to reduced activity of the synthetic enzymes glutamate-cysteine ligase and glutathione synthetase. The mechanistic rationale is that NAC undergoes deacetylation to cysteine in the intestinal mucosa and liver, while supplemental glycine directly enters the glutathione synthetic pathway; co-administration of both precursors at physiologically relevant doses corrects the dual substrate deficit and restores intracellular glutathione concentrations within two weeks in human subjects, with downstream improvements in oxidative stress biomarkers, mitochondrial fatty-acid oxidation, inflammation, insulin resistance, endothelial function, genomic integrity, and cellular senescence markers.

    The principal clinical evidence derives from a series of trials conducted at Baylor College of Medicine. A subsequent double-blind, placebo-controlled randomized clinical trial in 24 older adults (aged 65 to 80 years) confirmed these findings over 16 weeks of supplementation, with additional demonstration of improvements in multiple hallmarks of aging including mitochondrial dysfunction, impaired mitophagy, inflammation, endothelial dysfunction, genomic damage, stem cell fatigue, and cellular senescence.

    Parallel investigations have extended the GlyNAC evidence base to HIV-infected adults (open-label, improvements in oxidative stress, mitochondrial function, inflammation, endothelial function, insulin resistance, strength, and cognition), type 2 diabetes (pilot study, 30 percent improvement in mitochondrial fatty-acid oxidation and 22 percent reduction in insulin resistance over 14 days), and COVID-19 (observational characterization of severe glutathione deficiency and oxidative stress in hospitalized patients). A preclinical mouse lifespan study demonstrated that GlyNAC supplementation initiated at 65 weeks of age (corresponding to late middle age in humans) extended median lifespan by 24 percent and corrected glutathione deficiency, oxidative stress, mitochondrial dysfunction, impaired mitophagy, abnormal nutrient sensing, and genomic damage in liver, heart, and kidney tissues.

    The combination is well tolerated in all published trials. No serious adverse events attributable to GlyNAC have been reported. The principal mild adverse events are gastrointestinal (nausea, bloating), attributable to the NAC component, and are dose-dependent and generally self-limiting. NAC has an established clinical safety profile as a mucolytic and acetaminophen-overdose antidote at doses substantially exceeding those used in GlyNAC research.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Procyanidin C1

    B-type proanthocyanidin trimer (oligomeric flavan-3-ol) with senolytic, senomorphic, and multi-target anti-inflammatory activity

    A naturally occurring epicatechin trimer from grape seed extract identified as a dual-mode senotherapeutic agent that selectively eliminates senescent cells at high concentrations while suppressing the senescence-associated secretory phenotype at low concentrations, with demonstrated lifespan extension in mice and emerging preclinical evidence across fibrotic, neurodegenerative, and oncologic indications.

    Abstract

    Procyanidin C1 (PCC1) is a B-type proanthocyanidin trimer composed of three (2R,3R)-(-)-epicatechin units joined by two successive (4beta to 8)-interflavan bonds, with molecular formula C45H38O18 and molecular weight 866.77 g/mol. The compound is a polyphenolic constituent of grape seed extract (GSE), cocoa, cinnamon bark, unripe apple peel, and pine bark, and was first structurally characterized in the 1980s as part of the broader oligomeric proanthocyanidin (OPC) family originally described by Masquelier in 1947. PCC1 remained a minor analytical curiosity within the proanthocyanidin literature until 2021, when a landmark screening study by Xu, Fu, and colleagues, published in Nature Metabolism, identified PCC1 as a potent and selective senotherapeutic agent capable of extending healthspan and lifespan in aged mice through dual-mode activity on senescent cells [1]. At low concentrations (below approximately 50 micromolar), PCC1 acts as a senomorphic agent, suppressing the production of pro-inflammatory senescence-associated secretory phenotype (SASP) factors through inhibition of NF-kappaB signaling without inducing senescent cell death. At higher concentrations (above approximately 100 micromolar), PCC1 transitions to a senolytic mode, selectively inducing apoptosis in senescent cells through a reactive oxygen species (ROS)-dependent mitochondrial dysfunction pathway involving the p53-Puma/Noxa axis, while sparing proliferating and quiescent non-senescent cells. This concentration-dependent functional switch distinguishes PCC1 from most other characterized senolytic agents and provides a pharmacological basis for dose-titrated senotherapeutic intervention.

    Subsequent preclinical studies have expanded the evidence base substantially. Zhu, Huang, and colleagues (2024) demonstrated that PCC1 alleviates structural and functional decline in the aged mouse retina through combined senolytic and senomorphic mechanisms [2]. Gan and colleagues (2025) reported that PCC1 alleviates renal fibrosis by promoting apoptosis of senescent renal tubular epithelial cells [3]. Additional preclinical evidence supports activity against skin fibrosis through EGFR inhibition and TGF-beta/SMAD pathway suppression [4], neuroprotection through Nrf2/HO-1 signaling activation [5], endothelial nitric oxide production through PI3K/Akt-dependent eNOS phosphorylation [6], insulin sensitization in adipocytes through AKT-eNOS pathway activation [7], and colon cancer growth inhibition through miR-501-3p/HIGD1A axis modulation [8]. Single-cell profiling has revealed broad geroprotective effects on the hematopoietic immune system, including restoration of B cell and hematopoietic stem cell populations and suppression of senescence-associated inflammatory markers [9].

    Pharmacokinetically, PCC1 shares the absorption limitations characteristic of oligomeric proanthocyanidins: oral bioavailability of trimeric procyanidins is low, with the majority of ingested material reaching the colon intact where it is degraded by gut microbiota into phenylvalerolactones, phenylvaleric acids, and smaller phenolic acid metabolites. Phytosomal formulations have demonstrated 2- to 3-fold improvements in gastrointestinal absorption efficiency. No completed Phase 1 or Phase 2 clinical trials of purified PCC1 have been published as of the most recent monograph revision, though preliminary findings from phytosomal PCC1 formulations have shown reductions in senescence markers in peripheral blood mononuclear cells from elderly individuals. The compound is not approved by any regulatory authority for therapeutic use. It is available as a research-grade preparation from multiple chemical suppliers at greater than 95 percent purity by HPLC. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Zelquistinel

    Novel positive allosteric modulator of the N-methyl-D-aspartate receptor acting at a unique extracellular binding site independent of the glycine co-agonist site

    A third-generation, orally bioavailable spirocyclic beta-lactam NMDA receptor modulator developed from the rapastinel peptidomimetic platform, distinguished by nanomolar positive allosteric modulation of NR2A-, NR2B-, and NR2C-containing NMDA receptors through reduction of calcium-dependent inactivation, producing rapid and sustained antidepressant-like effects without psychotomimetic liability.

    Abstract

    Zelquistinel (GATE-251, formerly AGN-241751) is a novel, orally bioavailable, small-molecule positive allosteric modulator of the N-methyl-D-aspartate (NMDA) glutamate receptor, currently in Phase 2b clinical development for major depressive disorder (MDD) under the sponsorship of Syndeio Biosciences (operating as Gate Neurosciences). The compound is the third-generation successor to the tetrapeptide rapastinel (GLYX-13) and the dipeptide apimostinel (NRX-1074), sharing a common mechanism of NMDA receptor positive modulation but replacing the peptide scaffold with a spirocyclic 2,5-diazaspiro[3.4]octane (beta-lactam) core that confers oral bioavailability approaching 100 percent in preclinical species, a plasma half-life of approximately 1.2 to 2.1 hours, and approximately 1000-fold greater potency than rapastinel on a weight basis.

    Zelquistinel binds to a unique extracellular site on the NMDA receptor that is distinct from the glutamate agonist site, the glycine co-agonist site, the phencyclidine channel-blocking site, and the polyamine modulatory site. The compound does not displace radioligands at any of these four canonical sites and shows no significant activity across a panel of 80 receptors, ion channels, and monoamine transporters. Mechanistically, zelquistinel acts through a long-distance allosteric pathway: extracellular binding reduces intracellular calcium-dependent inactivation (CDI) of the NMDA receptor channel, thereby enhancing NMDA receptor current in an activity-dependent manner. This mechanism has been demonstrated through experiments showing that replacement of the intracellular calcium chelator EGTA with the fast chelator BAPTA abolishes zelquistinel potentiation, and that removal of the NR1 C-terminal intracellular domain or infusion of calmodulin-blocking peptide similarly eliminates the modulatory effect. Subtype selectivity studies reveal potent enhancement at NR2A-containing (EC50 approximately 9.9 nM) and NR2C-containing (EC50 approximately 9.7 nM) receptors, with a larger ceiling enhancement at NR2B-containing receptors (EC50 approximately 35.0 nM) and no effect at NR2D-containing receptors.

    The pharmacological profile produces a characteristic biphasic, inverted-U dose-response relationship: potentiation of NMDA receptor-mediated calcium influx at concentrations of 0.3 to 60 nM and mild inhibition at concentrations exceeding 100 nM. The compound enhances long-term potentiation (LTP) in both medial prefrontal cortex and hippocampal Schaffer collateral-CA1 pathways, with metaplastic enhancement persisting for at least two weeks after a single dose.

    A Phase 2a exploratory trial in 251 patients with major depressive disorder demonstrated statistically significant reductions in Montgomery-Asberg Depression Rating Scale (MADRS) scores at the two highest once-weekly oral doses (reductions of 9.5 and 10.6 points versus 7.7 points with placebo at week three). The U.S. Food and Drug Administration granted Fast Track designation for zelquistinel in MDD in July 2018. As of the date of this monograph, a Phase 2b confirmatory trial is actively recruiting under Syndeio Biosciences sponsorship. Additional preclinical research has demonstrated durable relief of core behavioral deficits in three mouse models of autism spectrum disorder, and dose-dependent reversal of phencyclidine-induced hyperlocomotion, expanding the potential therapeutic scope beyond depression.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Bemitil

    Benzimidazole-derived synthetic actoprotector with antihypoxant, antioxidant, and immunomodulatory activity

    A Soviet-developed 2-ethylthiobenzimidazole actoprotector that enhances physical and cognitive performance through genomic activation of protein synthesis, gluconeogenesis enzyme induction, and mitochondrial bioenergetic optimization, distinguished from classical psychostimulants by a non-exhaustive, adaptogenic mechanism that does not increase oxygen consumption or heat production.

    Abstract

    Bemitil (2-ethylthiobenzimidazole hydrobromide; synonyms bemethyl, metaprot, antihot) is the reference compound of the actoprotector drug class, a category of synthetic adaptogens defined by the capacity to enhance physical performance under normal and extreme conditions without increasing oxygen consumption or thermogenesis. Developed in the 1970s at the S.M. Kirov Military Medical Academy in Leningrad by Professor Vladimir Vinogradov and colleagues, bemitil was the first actoprotector to receive state registration in the Soviet Union (1983, registration number 83/654/1) and was subsequently deployed in military, aerospace, and athletic applications including cosmonaut preparation, Soviet national team conditioning for the 1980 Moscow Olympic Games, and operational support during the Afghan campaign and Chernobyl disaster response.

    The molecular pharmacology of bemitil is characterized by genomic activation of RNA and protein synthesis, a property attributable to the structural similarity of the benzimidazole nucleus to the purine bases adenine and guanine. The downstream consequences of this genomic activation include induction of gluconeogenesis enzymes in liver and kidney (accelerating lactate recycling to glucose through the Cori and glucose-alanine cycles), enhanced synthesis of mitochondrial respiratory chain enzymes and structural proteins (increasing ATP production and maintaining oxidative phosphorylation coupling), and upregulation of endogenous antioxidant enzymes including superoxide dismutase, catalase, and glutathione metabolism enzymes. The compound additionally demonstrates antihypoxic activity through maintenance of anaerobic ATP synthesis under oxygen deficit, neuroprotective activity in experimental stroke models, antimutagenic activity against alkylating agent-induced chromosomal aberrations, and immunomodulatory effects through protein synthesis-dependent augmentation of cellular immunity.

    Pharmacokinetics after oral administration are characterized by rapid gastrointestinal absorption (detectable in plasma within 30 minutes), peak effect at 1 to 2 hours with duration of 4 to 6 hours, active hepatic metabolism through cytochrome P450 isoforms CYP1A2, CYP2C9, CYP2D6, and CYP3A4, and urinary elimination predominantly as phase II conjugates. Nine metabolites have been identified in rat urine, with a benzimidazole-acetylcysteine conjugate (molecular formula C12H13N3O3S) representing the most abundant urinary metabolite, consistent with glutathione S-transferase-mediated detoxification. The compound exhibits tissue accumulation on prolonged dosing, with blood concentration increases observed by days 10 to 12 of continuous administration, necessitating cyclical dosing protocols (5 days on, 2 days off) in the registered prescribing information.

    Clinical applications span physical performance enhancement, post-exertional recovery acceleration, treatment of asthenic disorders of diverse etiology (neurasthenia, post-infectious asthenia, postoperative asthenia), and adjunctive therapy in cerebral trauma, meningitis, encephalitis, and cerebrovascular disorders. In a comparative clinical trial of 130 patients with asthenic conditions, bemitil demonstrated superior efficacy to the nootropics piracetam and pyriditol in reducing asthenic symptoms. The compound is generally well tolerated; the principal adverse events are gastrointestinal discomfort, headache, facial flushing, and sleep disturbance when administered in the evening. Contraindications include hypoglycemia, hepatic dysfunction, epilepsy, and pregnancy. The World Anti-Doping Agency placed bemitil on its Monitoring Program in 2018, and detection methods based on UPLC-MS/MS of the parent compound and its glucuronide conjugate in urine have been validated with detection windows extending beyond 30 days post-administration.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Hemantane

    Aminoadamantane derivative with low-affinity noncompetitive NMDA receptor antagonism, selective MAO-B inhibition, and dopaminergic modulation

    An aminoadamantane-class antiparkinsonian agent developed at the Zakusov Institute of Pharmacology in Russia, distinguished from amantadine and memantine by a hexamethylenimine substituent that confers a broader pharmacological spectrum encompassing NMDA receptor channel blockade, selective monoamine oxidase B inhibition, dopamine transporter modulation, and anti-inflammatory activity.

    Abstract

    Hemantane (N-(2-adamantyl)hexamethyleneimine hydrochloride; gimantan) is an experimental antiparkinsonian and neuroprotective agent of the aminoadamantane structural class, synthesized and developed at the V.V. Zakusov Research Institute of Pharmacology of the Russian Academy of Medical Sciences. The compound shares the adamantane cage scaffold with the clinically established agents amantadine and memantine but is distinguished by the attachment of a seven-membered azepane (hexamethylenimine) ring at the 2-position of the adamantane nucleus, a modification that broadens the pharmacological profile relative to the parent aminoadamantanes. Hemantane acts through multiple convergent mechanisms: it is a low-affinity, noncompetitive (uncompetitive) open-channel blocker of the N-methyl-D-aspartate (NMDA) subtype of the ionotropic glutamate receptor; a weak, competitive, selective inhibitor of monoamine oxidase B (MAO-B; Ki approximately 470 micromolar); a noncompetitive modulator of the dopamine transporter (DAT) that acutely reduces striatal dopamine reuptake Vmax by approximately 30 percent; a modulator of dopamine receptor subtype density (upregulating D1 and downregulating D2/D3 binding sites in the striatum after subchronic administration); and a putative sigma receptor agonist. The compound also exhibits anti-inflammatory activity in models of peripheral inflammation (acetic acid peritonitis, carrageenan-induced paw edema) and in a lipopolysaccharide-induced neuroinflammation model of Parkinson disease, where it attenuated weight loss, contralateral forepaw akinesia, and olfactory behavioral disruption.

    In preclinical parkinsonism models, hemantane (10 to 20 mg/kg intraperitoneally) reduced tremor, rigidity, and oligokinesia, and was reported to be superior to the reference drug amantadine in several behavioral paradigms. In the MPTP-treated C57BL/6 mouse model, subchronic hemantane administration increased dopamine transporter levels in multiple brain structures, a response broader than that produced by amantadine.

    Clinical evaluation of hemantane has been conducted in a randomized, double-blind, placebo-controlled Phase 2 trial in 60 patients with newly diagnosed, untreated early-stage Parkinson disease over 16 weeks. Safety monitoring (blood pressure, electrocardiogram, blood and urine parameters) did not identify dose-limiting toxicity at either dose. Additional preclinical research has demonstrated analgesic activity in somatic and visceral pain models, efficacy in reducing ethanol consumption in alcohol-experienced rats, attenuation of morphine withdrawal signs, and anti-arthritic activity when applied as a 5 percent topical gel formulation. The compound has not received marketing authorization in any jurisdiction and remains an investigational agent. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Pyrilutamide

    Nonsteroidal antiandrogen; selective, silent androgen receptor antagonist of the thiohydantoin structural class

    A topical nonsteroidal antiandrogen developed by Kintor Pharmaceuticals as a first-in-class selective silent antagonist of the androgen receptor for the treatment of androgenetic alopecia and acne vulgaris, distinguished from oral 5-alpha-reductase inhibitors by receptor-level blockade with minimal systemic exposure.

    Abstract

    Pyrilutamide (developmental code KX-826) is a nonsteroidal antiandrogen of the thiohydantoin structural class under clinical development by Suzhou Kintor Pharmaceuticals for the topical treatment of androgenetic alopecia (AGA) and acne vulgaris. The compound acts as a selective, high-affinity silent antagonist of the androgen receptor (AR), competitively displacing dihydrotestosterone (DHT) and testosterone from the ligand-binding domain without inducing any agonist-mediated transcriptional activity. This mechanism distinguishes pyrilutamide from systemic 5-alpha-reductase inhibitors (finasteride, dutasteride) that reduce circulating DHT concentrations, and from first-generation nonsteroidal antiandrogens (bicalutamide, flutamide) that possess residual partial agonist activity and are administered systemically. In cell-based AR transactivation assays, pyrilutamide exhibits an IC50 of approximately 0.28 nM, a Ki of 24 nM in competitive AR binding assays (compared to 48 nM for enzalutamide), and an IC50 of 264 nM for inhibition of prostate-specific antigen secretion in LNCaP prostate cancer cells, establishing it as one of the most potent topical antiandrogens characterized to date.

    The compound was designed for topical delivery to the scalp and skin, with molecular properties selected to favor dermal retention and limit transdermal penetration. Preclinical pharmacokinetic evaluation in rats demonstrated rapid distribution to skin and adipose tissue following topical application, with low transdermal bioavailability and negligible plasma exposure. In human clinical studies, peak plasma concentrations following application of the 0.5% topical formulation remained below 0.5 ng/mL, with an estimated dermal half-life of approximately 2 hours.

    Clinical development of pyrilutamide has proceeded through multiple trials across China and the United States. A Phase I ascending-dose safety study in 40 men in the United States (0.3% to 9.6% concentrations) demonstrated tolerability with only mild contact dermatitis as the principal adverse event. A Phase II randomized, placebo-controlled trial in 120 Chinese men with androgenetic alopecia (Norwood grades 3V, 4, and 5) reported that 0.5% pyrilutamide applied twice daily for 24 weeks produced a mean increase of 22.73 hairs per square centimeter in target area hair count (TAHC) from baseline, representing a 15.34 hairs per square centimeter advantage over placebo. A Phase II trial in Chinese women with female-pattern hair loss met its primary endpoint. A subsequent pivotal Phase III trial in Chinese men, however, failed to demonstrate statistical significance on the primary TAHC endpoint versus placebo at 24 weeks (announced November 2023). Long-term safety extensions at 52 weeks reported that 46% of patients achieved at least a 10 hairs per square centimeter increase and 20% achieved at least a 20 hairs per square centimeter increase, with no drug-related sexual dysfunction and a favorable overall safety profile. A reformulated 1.0% tincture is now under evaluation in a Phase II/III pivotal trial initiated in 2025, with enrollment exceeding 750 participants at more than 20 hospital sites. A Phase II trial for acne vulgaris has completed enrollment in China. No regulatory approval has been granted in any jurisdiction as of the date of this monograph.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • AMX0035

    Fixed-dose oral combination of sodium phenylbutyrate (chemical chaperone and HDAC inhibitor) and taurursodiol (bile acid cytoprotectant) targeting endoplasmic reticulum stress and mitochondrial dysfunction

    A proprietary two-component oral formulation developed by Amylyx Pharmaceuticals combining sodium phenylbutyrate and taurursodiol (tauroursodeoxycholic acid) to concurrently attenuate endoplasmic reticulum stress and mitochondrial apoptotic signaling in neurodegenerative disease, approved under accelerated pathway by the United States Food and Drug Administration in September 2022 for the treatment of amyotrophic lateral sclerosis in adults and subsequently withdrawn from the market in 2024 following failure to confirm efficacy in the confirmatory Phase 3 PHOENIX trial.

    Abstract

    The therapeutic rationale is simultaneous modulation of two convergent cell-death pathways implicated in motor neuron degeneration: endoplasmic reticulum (ER) stress, addressed by the chemical chaperone and histone deacetylase (HDAC) inhibitor activity of sodium phenylbutyrate, and mitochondrial apoptotic signaling, addressed by the bile acid cytoprotectant taurursodiol (the taurine conjugate of ursodeoxycholic acid). Sodium phenylbutyrate upregulates molecular chaperones including heat shock protein 70 (HSP70) and DJ-1, reduces accumulation of misfolded proteins in the ER lumen, and inhibits class I and class II histone deacetylases (excluding class III, HDAC6, and HDAC10), thereby promoting a transcriptional program favoring cell survival. Taurursodiol stabilizes the mitochondrial membrane by inhibiting Bax translocation, reducing mitochondrial permeability transition pore opening, and raising the apoptotic threshold by preventing cytochrome c release into the cytosol. In preclinical models, the combination produced synergistic reduction of hydrogen peroxide-induced neuronal cell death beyond either component alone.

    The clinical evidence base for AMX0035 in ALS rests principally on the Phase 2 CENTAUR trial (NCT03127514), a 24-week, randomized, double-blind, placebo-controlled study conducted across 25 Northeast ALS Consortium (NEALS) sites in 137 participants with ALS of no more than 18 months symptom duration [1]. The primary endpoint was the rate of decline on the ALS Functional Rating Scale-Revised (ALSFRS-R): participants receiving AMX0035 showed a mean decline of 1.24 points per month versus 1.66 points per month on placebo, a difference of 0.42 points per month (95% CI 0.03 to 0.81; p = 0.03). Long-term survival analysis of the CENTAUR cohort showed a median survival advantage of 6.5 months favoring those originally randomized to AMX0035 (hazard ratio 0.57; 95% CI 0.35 to 0.92; p = 0.023) [2]. On the basis of these Phase 2 data and an external-control survival analysis, the FDA granted accelerated approval to Relyvrio on September 29, 2022, for the treatment of ALS in adults. Health Canada had previously granted approval to Albrioza in June 2022.

    The confirmatory Phase 3 PHOENIX trial (NCT05021536), a 48-week, randomized, placebo-controlled study in 664 adults with ALS, did not meet its primary endpoint of slowing ALSFRS-R decline (p = 0.667) or any secondary endpoints [3]. No significant treatment effect was observed even in the subset of participants who met the original CENTAUR eligibility criteria. Following the PHOENIX results, Amylyx Pharmaceuticals discontinued marketing of Relyvrio as of October 31, 2024, and submitted a formal request for withdrawal of FDA approval on February 28, 2025. The European Medicines Agency had previously declined to authorize the compound for marketing in the European Union.

    A separate Phase 2 trial (PEGASUS) evaluated AMX0035 in 96 adults with mild cognitive impairment or dementia due to Alzheimer disease over 24 weeks [4]. The trial met its primary endpoint of safety and tolerability but did not demonstrate slowing of cognitive decline. AMX0035 produced significant reductions in cerebrospinal fluid biomarkers of tau pathology (phosphorylated tau 181 and total tau, both p < 0.001) and modulation of the amyloid beta 42/40 ratio (p < 0.05), suggesting biological activity on core Alzheimer disease pathology despite the absence of a clinical cognitive signal in this short-duration study.

    The pharmacokinetics of the two components are well characterized independently. Sodium phenylbutyrate is rapidly absorbed (Tmax approximately 1 hour), with a plasma half-life of approximately 0.76 hours, and is metabolized by beta-oxidation to phenylacetate (half-life approximately 1.2 hours) and subsequently conjugated with glutamine to form phenylacetylglutamine, which is renally excreted. Taurursodiol, a hydrophilic bile acid conjugate, undergoes hepatic first-pass extraction via bile acid transporters, enters the enterohepatic circulation, and is metabolized by intestinal bacteria; systemic bioavailability is limited by efficient hepatic uptake. The combination is administered as a powder for oral suspension, mixed in 250 milliliters of water, taken once daily for the first three weeks and twice daily thereafter. The principal adverse events are gastrointestinal (diarrhea, abdominal pain, nausea), occurring predominantly during the first three weeks of dosing, with rates of discontinuation due to adverse events of approximately 19 percent in the CENTAUR trial compared to 8 percent on placebo.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • BPN14770

    First-in-class allosteric inhibitor of phosphodiesterase-4D (PDE4D) with subtype selectivity and primate-specific potency enhancement

    A PDE4D-selective allosteric inhibitor developed by Tetra Therapeutics (Shionogi) that enhances cAMP-PKA-CREB signaling to promote memory consolidation, synaptic plasticity, and neuroprotection, distinguished from classical PDE4 inhibitors by subtype selectivity and a wide therapeutic window separating cognitive benefit from emetic side effects.

    Abstract

    BPN14770 (zatolmilast) is a first-in-class, subtype-selective, allosteric inhibitor of phosphodiesterase-4D (PDE4D) that was discovered at Tetra Discovery Partners (later Tetra Therapeutics) and is currently in late-stage clinical development under Shionogi, which acquired Tetra in May 2020. The compound is distinguished from the two approved PDE4 inhibitors (roflumilast and apremilast) and from the classical PDE4 research tool rolipram by three principal features: allosteric rather than competitive inhibition of the PDE4D catalytic site, high selectivity for the PDE4D subtype over PDE4A, PDE4B, and PDE4C (approximately 730-fold selectivity over PDE4B), and exploitation of a primate-specific amino acid residue in the PDE4D N-terminal regulatory domain (UCR2 helix) that confers approximately 100-fold greater potency in humanized transgenic mice relative to wild-type mice, while simultaneously producing low potency in the xylazine/ketamine emesis surrogate assay. These properties yield a therapeutic index of 40- to 100-fold between plasma exposures that produce cognitive and neurochemical benefit (10 to 30 ng/mL) and those projected to cause emesis in non-rodent species (approximately 1,300 ng/mL), a margin that has historically been the dose-limiting constraint for PDE4 inhibitors in cognitive indications.

    The molecular pharmacology of BPN14770 is centered on the cAMP-PKA-CREB signaling cascade. Inhibition of PDE4D elevates intracellular cyclic adenosine monophosphate (cAMP) in hippocampal and cortical neurons, activating protein kinase A (PKA), which phosphorylates the transcription factor CREB (cAMP response element-binding protein). Phosphorylated CREB drives expression of brain-derived neurotrophic factor (BDNF), synapsin, postsynaptic density protein 95 (PSD-95), and other effectors of synaptic plasticity and memory consolidation. A separate pathway analysis confirmed that BPN14770 engages the cAMP-PKA-SIRT1-Akt-Bcl-2/Bax signaling module, producing neuroprotective and anti-apoptotic effects.

    The Phase 1 trials established linear pharmacokinetics, oral bioavailability of 70 to 80 percent, a plasma half-life of 8 to 10 hours, and a brain-to-plasma ratio of approximately 0.4. The PICASSO Alzheimer’s trial missed its primary endpoint (RBANS Delayed Memory Index) but showed a signal on the Clinical Dementia Rating Sum of Boxes (CDR-SB) in a higher-dose subgroup. The Fragile X Phase 2 trial met its primary endpoint of safety and tolerability and demonstrated significant improvement on NIH Toolbox Oral Reading Recognition, Picture Vocabulary, and Cognition Crystallized Composite Score, with clinically significant caregiver-rated improvement in language and daily functioning. Shionogi subsequently initiated the EXPERIENCE Phase 2b/3 program comprising three studies (EXPERIENCE-204 in adolescents, EXPERIENCE-301 in adults, EXPERIENCE-302 open-label extension) for Fragile X syndrome. Topline results from the Phase 3 trials indicated that neither study met its originally specified primary endpoint of cognitive improvement on the NIH Toolbox, though the adult study (EXPERIENCE-301) showed statistically significant improvement on the caregiver-assessed Numeric Rating Scale. The compound holds FDA Fast Track designation, Orphan Drug designation in both the United States and European Union, and Rare Pediatric Disease designation for Jordan’s syndrome (Houge-Janssens syndrome 1), for which a Phase 2 trial enrolling 30 participants was initiated in February 2025.

    The compound is well tolerated in clinical studies. The most common adverse events are headache, transient nausea, and vomiting, occurring at rates modestly above placebo. No serious adverse events attributable to the compound have been reported. The favorable emetic profile relative to classical PDE4 inhibitors reflects the allosteric mechanism and PDE4D subtype selectivity, which avoid the PDE4B-mediated emesis that limits rolipram and constrains roflumilast dosing.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.